<!DOCTYPE html>
<html>
<head>
    <title>Clinical Report - SAMPLE001</title>
    <style>
        @media print { .no-print { display: none; } }
        body { font-family: 'Helvetica Neue', Arial, sans-serif; margin: 0; padding: 0; background: #f8f9fa; }
        .header { background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white; padding: 30px; text-align: center; }
        .header h1 { margin: 0; font-size: 28px; font-weight: 300; }
        .header .subtitle { margin-top: 10px; opacity: 0.9; font-size: 14px; }
        .container { max-width: 900px; margin: 20px auto; background: white; padding: 40px; box-shadow: 0 0 20px rgba(0,0,0,0.1); }
        .section { margin: 30px 0; padding: 20px; border-left: 4px solid #667eea; background: #f8f9fa; }
        .section h2 { margin-top: 0; color: #2d3748; }
        table { width: 100%; border-collapse: collapse; margin: 15px 0; }
        th, td { padding: 12px; text-align: left; border-bottom: 1px solid #e2e8f0; }
        th { background: #edf2f7; font-weight: 600; color: #2d3748; }
        .pathogenic { background: #fed7d7; color: #9b2c2c; padding: 3px 8px; border-radius: 4px; font-weight: 600; }
        .likely-pathogenic { background: #feebc8; color: #7c2d12; padding: 3px 8px; border-radius: 4px; font-weight: 600; }
        .vus { background: #e6fffa; color: #234e52; padding: 3px 8px; border-radius: 4px; font-weight: 600; }
        .benign { background: #c6f6d5; color: #22543d; padding: 3px 8px; border-radius: 4px; font-weight: 600; }
        .warning-box { background: #fffbeb; border-left: 4px solid #f59e0b; padding: 15px; margin: 20px 0; }
        .info-box { background: #eff6ff; border-left: 4px solid #3b82f6; padding: 15px; margin: 20px 0; }
        .gene { font-weight: 700; color: #5a67d8; }
        .footer { margin-top: 40px; padding-top: 20px; border-top: 2px solid #e2e8f0; color: #718096; font-size: 12px; text-align: center; }
    </style>
</head>
<body>
    <div class="header">
        <h1>üß¨ CLINICAL NGS ANALYSIS REPORT</h1>
        <div class="subtitle">Patient-Centric Genomic Medicine</div>
    </div>
    
    <div class="container">
        <div class="section">
            <h2>Patient Information</h2>
            <table>
                <tr><th>Sample ID</th><td>SAMPLE001</td></tr>
                <tr><th>Analysis Type</th><td>Germline (Constitutional)</td></tr>
                <tr><th>Panel</th><td>Clinical Exome (4,800 genes)</td></tr>
                <tr><th>Report Date</th><td>February 1, 2026</td></tr>
                <tr><th>Analyst</th><td>Prabir Kumar | Clinical Bioinformatician</td></tr>
            </table>
        </div>
        
        <div class="section">
            <h2>Quality Metrics Summary</h2>
            <table>
                <tr>
                    <th>Metric</th>
                    <th>Value</th>
                    <th>Threshold</th>
                    <th>Status</th>
                </tr>
                <tr>
                    <td>Mean Target Coverage</td>
                    <td>185x</td>
                    <td>‚â•100x</td>
                    <td>‚úÖ PASS</td>
                </tr>
                <tr>
                    <td>% Targets at 50x</td>
                    <td>98.5%</td>
                    <td>‚â•95%</td>
                    <td>‚úÖ PASS</td>
                </tr>
                <tr>
                    <td>Uniformity (% ¬±20%)</td>
                    <td>94.2%</td>
                    <td>‚â•85%</td>
                    <td>‚úÖ PASS</td>
                </tr>
                <tr>
                    <td>On-Target Rate</td>
                    <td>89.3%</td>
                    <td>‚â•80%</td>
                    <td>‚úÖ PASS</td>
                </tr>
            </table>
        </div>
        
        <div class="section">
            <h2>Clinically Significant Variants</h2>
            
            <div class="warning-box">
                <strong>‚ö†Ô∏è PATHOGENIC VARIANT DETECTED</strong>
            </div>
            
            <table>
                <thead>
                    <tr>
                        <th>Gene</th>
                        <th>Variant</th>
                        <th>Type</th>
                        <th>VAF</th>
                        <th>Classification</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><span class="gene">BRCA1</span></td>
                        <td>c.5266dupC (p.Gln1756fs)</td>
                        <td>Frameshift</td>
                        <td>52.3%</td>
                        <td><span class="pathogenic">PATHOGENIC</span></td>
                    </tr>
                    <tr>
                        <td><span class="gene">TP53</span></td>
                        <td>c.743G>A (p.Arg248Gln)</td>
                        <td>Missense</td>
                        <td>48.7%</td>
                        <td><span class="likely-pathogenic">LIKELY PATHOGENIC</span></td>
                    </tr>
                    <tr>
                        <td><span class="gene">CHEK2</span></td>
                        <td>c.1100delC (p.Thr367fs)</td>
                        <td>Frameshift</td>
                        <td>51.2%</td>
                        <td><span class="pathogenic">PATHOGENIC</span></td>
                    </tr>
                </tbody>
            </table>
            
            <div class="info-box">
                <strong>Clinical Interpretation:</strong><br>
                <strong>BRCA1 c.5266dupC:</strong> Well-established pathogenic variant associated with hereditary breast and ovarian cancer syndrome. 
                Lifetime risk: Breast cancer ~72%, Ovarian cancer ~44%. Recommend genetic counseling and consideration of enhanced surveillance or risk-reducing surgery.<br><br>
                
                <strong>TP53 c.743G>A:</strong> Hotspot mutation in DNA-binding domain. Associated with Li-Fraumeni syndrome. 
                Recommend multi-organ surveillance protocol.<br><br>
                
                <strong>CHEK2 c.1100delC:</strong> Moderate-penetrance breast cancer risk allele. 
                2-3 fold increased lifetime risk. Consider enhanced mammographic screening.
            </div>
        </div>
        
        <div class="section">
            <h2>Variants of Uncertain Significance (VUS)</h2>
            <table>
                <thead>
                    <tr>
                        <th>Gene</th>
                        <th>Variant</th>
                        <th>Classification</th>
                        <th>Note</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><span class="gene">ATM</span></td>
                        <td>c.8147A>G (p.Tyr2716Cys)</td>
                        <td><span class="vus">VUS</span></td>
                        <td>Insufficient evidence for pathogenicity</td>
                    </tr>
                    <tr>
                        <td><span class="gene">PALB2</span></td>
                        <td>c.2521C>T (p.Arg841Trp)</td>
                        <td><span class="vus">VUS</span></td>
                        <td>Novel variant, not in ClinVar</td>
                    </tr>
                </tbody>
            </table>
        </div>
        
        <div class="section">
            <h2>Pharmacogenomics</h2>
            <table>
                <tr>
                    <th>Gene</th>
                    <th>Phenotype</th>
                    <th>Clinical Implication</th>
                </tr>
                <tr>
                    <td><span class="gene">CYP2D6</span></td>
                    <td>*1/*4 (Intermediate Metabolizer)</td>
                    <td>Reduced metabolism of codeine, tamoxifen. Consider alternative agents.</td>
                </tr>
                <tr>
                    <td><span class="gene">DPYD</span></td>
                    <td>*1/*1 (Normal Activity)</td>
                    <td>Standard 5-FU dosing appropriate</td>
                </tr>
            </table>
        </div>
        
        <div class="section">
            <h2>Technical Notes & Limitations</h2>
            <ul>
                <li>Analysis based on GRCh38/hg38 reference genome</li>
                <li>Variant caller: GATK HaplotypeCaller v4.5.0.0</li>
                <li>This test does not detect large deletions, duplications, or structural variants</li>
                <li>Regions with coverage <20x are flagged and may require orthogonal validation</li>
                <li>Mosaic variants with VAF <15% may not be reliably detected</li>
                <li>Intronic variants >20bp from exon boundaries are not assessed</li>
            </ul>
        </div>
        
        <div class="section">
            <h2>Recommendations</h2>
            <ol>
                <li><strong>Genetic Counseling:</strong> Strongly recommended for discussion of pathogenic BRCA1 and TP53 variants</li>
                <li><strong>Family Cascade Testing:</strong> Consider testing first-degree relatives for identified pathogenic variants</li>
                <li><strong>Surveillance:</strong> Enhanced screening protocol per NCCN guidelines for hereditary cancer syndromes</li>
                <li><strong>Clinical Correlation:</strong> Integrate findings with family history and clinical presentation</li>
            </ol>
        </div>
        
        <div class="footer">
            <p><strong>Clinical NGS Pipeline v2.0</strong></p>
            <p>This report was generated using validated bioinformatics pipelines maintained by Prabir Kumar</p>
            <p>For questions, contact: clinical.genomics@example.org</p>
            <p style="margin-top: 15px; font-size: 10px;">
                DISCLAIMER: This report is for clinical interpretation by qualified healthcare professionals. 
                Genetic counseling is recommended before making clinical decisions based on these results.
            </p>
        </div>
    </div>
</body>
</html>
